Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Submitted by
admin
on July 9, 2018 - 10:51am
Source:
CP Wire
News Tags:
edasalonexent
clinical trials
Duchenne Muscular Dystrophy
Headline:
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
snippet:
Plans to initiate trial in second half of 2018
Edasalonexent significantly slowed progression in Ph II trial
Edasalonexent is being developed as monotherapy or for use in combination
Do Not Allow Advertisers to Use My Personal information
